RGD-IL-24, A Novel Tumor-Targeted Fusion Cytokine: Expression, Purification and Functional Evaluation
| Autor: | Xuhu Mao, Wei Li, Gang Guo, Jun Yang, Bin Xiao, Quanming Zou |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Recombinant Fusion Proteins
medicine.medical_treatment Integrin Bioengineering Applied Microbiology and Biotechnology Biochemistry Drug Delivery Systems Cell Line Tumor Neoplasms Interleukin 24 Cell Adhesion medicine Humans Molecular Biology Cell Proliferation biology Cell growth Interleukins Cancer Interleukin medicine.disease Cytokine Cell culture Cancer cell biology.protein Cancer research Female Oligopeptides Biotechnology |
| Zdroj: | Molecular Biotechnology. 41:138-144 |
| ISSN: | 1559-0305 1073-6085 |
| Popis: | Targeting drugs to tumor cells is a central challenge for improving existing cancer therapies. ACDCRGDCFCG peptide (RGD-4C) binds to alphavbeta3 integrin, which is selectively expressed in tumor blood vessels and on the surface of some tumor cells. Interleukin 24 (IL-24) is a novel cancer growth-suppressing and apoptosis-inducing cytokine. To enhance the antitumor effect, we coupled RGD-4C to the N-terminus of IL-24 and expressed RGD-IL-24 in Escherichia coli. Cell proliferation and adhesion experiments revealed that RGD-IL-24 specifically binds to MCF-7 cancer cells, and induces apoptosis of MCF-7 cancer cells. These studies support the use of the RGD-IL-24 protein in tumor-targeting therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink